The Food and Drug Administration (FDA) has approved Soaanz® (torsemide) for the treatment of edema associated with heart failure or renal disease in adults.

Soaanz is a loop diuretic with an extended duration of action lasting approximately 6 to 8 hours, with a peak effect that occurs within the first 4 hours. According to the Company, Soaanz is formulated to reduce excessive urination and may reduce the incidence of hypokalemia. The mean increase in potassium excretion over 23 hours after a single oral dose of Soaanz 20mg in healthy adults was 12.7mEq.

Soaanz is supplied as 20mg and 60mg tablets in 30- and 90-count bottles and is expected to be available in the next few months. 

Continue Reading

“Sarfez Pharmaceuticals benefited from grant funding made available by the Small Business Administration and National Institute of Diabetes and Digestive and Kidney Diseases during our development of Soaanz,” said Salim Shah, PhD, JD, Founder and Chairman, Sarfez Pharmaceuticals. “We are thankful for that support, and we plan to transfer that benefit on to our patients by offering Soaanz at a reasonable price.”

References

  1. FDA approves Soaanz for edema treatment in patients with heart failure and renal disease. [press release]. Vienna, VA: Sarfez Pharmaceuticals Inc.; June 21, 2021. 
  2. Soaanz [package insert]. Vienna, VA: Sarfez Pharmaceuticals Inc.; 2021.

This article originally appeared on MPR

Topics:

Cardiovascular Disease Chronic Kidney Disease Heart Failure